Led · Series A · Nov 2025

HyPrSpace is an aerospace company focused on creating Orbital Baguette 1 (OB-1), a hybrid microlauncher designed to make access to orbit easier and more affordable. The OB-1 vehicle combines solid and liquid propulsion technologies and is engineered to transport payloads of up to 250 kilograms. Proceeds from its recent fundraising will be used to speed up engineering, ground-testing, and manufacturing activities. The company’s roadmap targets a first suborbital demonstration flight in 2026, a key milestone toward eventual orbital missions. Based in Bordeaux, HyPrSpace positions itself within France’s deep-tech ecosystem, taking advantage of national initiatives such as France 2030. Although revenue and user metrics have not been disclosed, the €21 million injection represents a significant step toward commercial readiness.

Participated · Series B · May 2025

Veesion develops AI technology that detects suspicious gestures in physical retail environments to help prevent shoplifting. Led by CEO Thibault David, the company says its solution has revolutionized store security and broadened AI accessibility for professionals. Its product is used in over 5,000 stores across 25 countries, spanning independent shops and large supermarket chains. The company plans to extend its technology into new environments and use cases. Veesion intends to use new funding to support international expansion and product extension.

Led · Equity · Apr 2025

Okeiro, formerly Predict4Health and based in Paris, builds an advanced clinical decision support platform that leverages AI to prevent organ failure across kidney, lung, heart and liver transplants and advanced chronic diseases. At the core of the platform is the iBox algorithm, a clinically validated predictive model developed with APHP and INSERM that is marked as a medical device and qualified as a surrogate endpoint by the FDA and EMA. The technology enables physicians to identify post-transplant complications, improve patient monitoring and treatment protocols, and accelerate clinical trial timelines. The platform is already implemented in transplant centers across France, is benefiting thousands of patients, and has achieved national reimbursement through the French National Health Insurance. Okeiro is currently running a randomized clinical trial across 16 hospital centers in six countries (France, Germany, the United Kingdom, Austria, Israel and Spain) to compare outcomes for physicians using the platform versus standard care; interim results are very positive and the study will complete in a few months. The company plans to use the newly raised funds to accelerate deployment in France and internationally and to develop new AI tools to further improve diagnostics, therapeutic recommendations, and clinical research in end-stage chronic disease and transplant patients.

Participated · Series C · Dec 2024

Jiko combines the protections of a regulated national bank with a modern technology stack that automatically invests deposits in U.S. Treasury bills, giving clients a safe, yield-generating alternative to traditional demand deposits. Its API-driven platform allows institutions to hold and move corporate cash, settle high-volume transactions in real time, and access liquidity 24/7. The company recently launched JikoNet, a continuous fiat-settlement network purpose-built for institutions that need round-the-clock U.S.-dollar transfers. Jiko’s privacy-first architecture minimizes counter-party risk while maintaining compliance through its broker-dealer, Jiko Securities, Inc., and its banking division, Jiko Bank. The model has attracted digital-asset firms that require faster, safer on- and off-ramps between fiat and crypto markets. Industry veteran Breanne Madigan has joined as Managing Director and Head of Digital Assets to accelerate penetration of the crypto and fintech sectors. Although the company did not disclose revenue or user figures, it highlighted growing institutional adoption through new partnerships with Coinbase, Crypto.com, Bitso, and Blockstream Capital Partners.

Led · Series A · Sep 2024

DeepOpinion builds an agentic, no-code AI platform that automates complex, knowledge-intensive back-office workflows by leveraging context-understanding capabilities and large language models. The platform adapts to any document type, connects to over 200 enterprise software tools, and uses self-optimising AI agents that learn from human feedback to enable touchless end-to-end processing. In insurance scenarios the company says it can automate claims in about 90 seconds versus human processing times of roughly five weeks after disasters. DeepOpinion's technology targets unstructured data from emails, documents, messages and forms to scale automation where traditional tools fall short. Clients across insurance, financial services and telecommunications include Siemens, e&, BitPanda, HannoverRE, Uelzener and Allianz. The company raised €11 million in a Series A to fund global expansion and further development of its core AI platform.